Influence of prostate volume on dosimetry results in real-time 125I seed implantation

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 1, 2004, Pages 292-299

  McNeely, Lee K ^a   Stone, Nelson N ^b,e   Presser, Joseph ^c   Chircus, Jeffrey H ^d   Stock, Richard G ^b  

^a Boulder Community Hospital   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ProSeed   (United States)

^d Northwest Hospital   (United States)

^e NONE   (United States)

Author keywords

125I brachytherapy; Postimplant dosimetry; Prostate volume

Indexed keywords

BIOCHEMISTRY; DOSIMETRY; IMPLANTS (SURGICAL); RADIOACTIVITY; TOXICITY;

BRACHYTHERAPY;

ONCOLOGY;

IODINE 125;

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE; RADIATION DOSE; RADIOACTIVITY; ULTRASOUND;

EID: 0346993528     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00783-1     Document Type: Article

References (36)

1. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 41:1998;101-108.
2. Stock R.G., Stone N.N., Kao J., et al. The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy. Cancer. 89:2000;1829-1834.
3. Stock R.G., Stone N.N., Dalal M., et al. What is the optimal dose for I-125 prostate implants? A dose response analysis of biochemical control, post-treatment biopsies, and long-term urinary symptoms. Brachytherapy. 1:2002;83-89.
4. Potters L., Cao Y., Calugaru E., et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 50:2001;605-614.
5. Lee W.R., deGuzman A.F., Bare R.L., et al. Postimplant analysis of transperineal interstitial permanent prostate brachytherapy - Evidence for a learning curve in the first year at a single institution. Int J Radiat Oncol Biol Phys. 46:2000;83-88.
6. Stock R.G., Stone N.N., Lo Y.C., et al. Postimplant dosimetry for I-125 prostate implants Definitions and factors affecting outcome . Int J Radiat Oncol Biol Phys. 48:2000;899-906.
7. Wilkinson D.A., Lee E.J., Ciezki J.P., et al. Dosimetric comparison of pre-planned and OR-planned prostate seed brachytherapy. Int J Radiat Oncol Biol Phys. 48:2000;1241-1244.
8. Stock R.G., Stone N.N., Lo Y.C. Intraoperative dosimetric representation of the real-time ultrasound guided prostate implant. Techn Urol. 6:2000;95-98.
9. Zelefsky M.J., Yamada Y., Cohen G., et al. Postimplantation dosimetric analysis of permanent transperineal prostate implantation Improved dose distributions with an intraoperative computer-optimized conformal planning technique . Int J Radiat Oncol Biol Phys. 48:2000;601-608.
10. Cormack R.A., Tempany C.M., D'Amico A.V. Optimizing target coverage by dosimetric feedback during prostate brachytherapy. Int J Radiat Oncol Biol Phys. 48:2000;1245-1249.
11. Moerland M.A., Wijrdeman H.K., Beersma R., et al. Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 37:1997;927-933.
12. Yu Y., Waterman F.M., Suntharalingam N., et al. Limitations of the minimum peripheral dose as a parameter for dose specification in permanent I-125 prostate implants. Int J Radiat Oncol Biol Phys. 34:1996;717-725.
13. Badiozamani K., Wallner K., Sutlief S., et al. Anticipating prostate volume changes due to prostate brachytherapy. Radiat Oncol Invest. 7:1999;360-364.
14. 3 Dosimetric analysis of implant quality . Int J Radiat Oncol Biol Phys. 46:2000;1199-1204.
15. Kang S.K., Chou R.H., Dodge R.K., et al. Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method. Int J Radiat Oncol Biol Phys. 50:2001;937-945.
16. Locke J., Ellis W., Wallner K., et al. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy A prospective study . Int J Radiat Oncol Biol Phys. 52:2002;712-719.
17. Gelblum D.Y., Potters L., Ashley R., et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 45:1999;59-67.
18. Lee N., Wuu C.-S., Brody R., et al. Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 48:2000;1457-1460.
19. Terk M.D., Stock R.G., Stone N.N. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol. 160:1998;1379-1382.
20. Merrick G.S., Butler W.M., Dorsey A.T., et al. Rectal dosimetric analysis following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 43:1999;1021-1027.
21. Snyder K.M., Stock R.G., Hong S.M., et al. Defining the risk of developing grade 2 proctitis following I-125 prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys. 50:2001;335-341.
22. Stone N.N., Stock R.G. Brachytherapy for prostate cancer Real-time three-dimensional interactive seed implantation . Techn Urol. 1:1995;72-80.
23. Stock R.G., Stone N.N., Wesson M.F., et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys. 32:1995;210-225.
24. Merrick G.S., Butler W.M., Dorsey A.T., et al. The dependence of prostate postimplant dosimetric quality on CT volume determination. Int J Radiat Oncol Biol Phys. 44:1999;1111-1117.
25. 90 in prostate brachytherapy Can implant quality be predicted on day 0? Int J Radiat Oncol Biol Phys. 53:2002;610-621.
26. Bice W.S., Prestidge B.R., Grimm P.D., et al. Centralized multi-institutional analysis for interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys. 41:1998;921-927.
27. Sherertz T., Wallner K., Wang H., et al. Long-term urinary function after transperineal brachytherapy for patients with large prostate glands. Int J Radiat Oncol Biol Phys. 51:2001;1241-1245.
28. Prestidge B.R., Bice W.S., Kiefer E.J., et al. Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys. 40:1998;1111-1115.
29. Willins J., Wallner K. CT-based dosimetry for transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 39:1997;347-353.
30. Crook J., Milosevic M., Catton P., et al. Interobserver variation in postimplant computed tomography contouring affects quality assessment of prostate brachytherapy. Brachytherapy. 1:2002;66-73.
31. Brown D., Colonias A., Miller R., et al. Urinary morbidity with a modified peripheral loading technique of transperineal I-125 prostate implantation. Int J Radiat Oncol Biol Phys. 47:2000;353-360.
32. Desai J., Stock R.G., Stone N.N., et al. Acute urinary morbidity following iodine-125 interstitial implantation of the prostate gland. Radiat Oncol Invest. 6:1998;135-141.
33. Wallner K., Jitendra R., Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 32:1995;465-471.
34. Yamada Y., Kim M., Cohen G., et al. An analysis of late urinary toxicity based upon urethra dose volume histograms after transperineal permanent interstitial iodine-125 prostate brachytherapy. [Abstract] Int J Radiat Oncol Biol Phys. 48:(Suppl.):2000;149.
35. Badiozamani K.R., Wallner K., Cavanaugh W., et al. Comparability of CT-based and TRUS-based prostate volumes. Int J Radiat Oncol Biol Phys. 43:1999;375-378.
36. Whittington R., Broderick G.A., Arger P., et al. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 44:1999;1107-1110.